METACRINE INC (MTCR) Fundamental Analysis & Valuation

NASDAQ:MTCR • US59101E1038

Current stock price

0.4949 USD
0 (-0.02%)
At close:
0.4701 USD
-0.02 (-5.01%)
After Hours:

This MTCR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MTCR Profitability Analysis

1.1 Basic Checks

  • MTCR had negative earnings in the past year.
  • MTCR had a negative operating cash flow in the past year.
MTCR Yearly Net Income VS EBIT VS OCF VS FCFMTCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -20M -40M -60M

1.2 Ratios

  • The profitability ratios for MTCR are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MTCR Yearly ROA, ROE, ROICMTCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MTCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTCR Yearly Profit, Operating, Gross MarginsMTCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MTCR Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, MTCR has more shares outstanding
  • MTCR has a worse debt/assets ratio than last year.
MTCR Yearly Shares OutstandingMTCR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
MTCR Yearly Total Debt VS Total AssetsMTCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

  • MTCR has an Altman-Z score of -5.64. This is a bad value and indicates that MTCR is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -5.64, MTCR is not doing good in the industry: 72.53% of the companies in the same industry are doing better.
  • MTCR has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
  • MTCR has a Debt to Equity ratio of 0.34. This is in the lower half of the industry: MTCR underperforms 75.20% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z -5.64
ROIC/WACCN/A
WACCN/A
MTCR Yearly LT Debt VS Equity VS FCFMTCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

  • MTCR has a Current Ratio of 12.15. This indicates that MTCR is financially healthy and has no problem in meeting its short term obligations.
  • MTCR's Current ratio of 12.15 is fine compared to the rest of the industry. MTCR outperforms 78.02% of its industry peers.
  • A Quick Ratio of 12.15 indicates that MTCR has no problem at all paying its short term obligations.
  • The Quick ratio of MTCR (12.15) is better than 78.02% of its industry peers.
Industry RankSector Rank
Current Ratio 12.15
Quick Ratio 12.15
MTCR Yearly Current Assets VS Current LiabilitesMTCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MTCR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 69.63% over the past year.
EPS 1Y (TTM)69.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 12.09% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y70.87%
EPS Next 2Y36.17%
EPS Next 3Y23.37%
EPS Next 5Y12.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTCR Yearly Revenue VS EstimatesMTCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 500K 1M
MTCR Yearly EPS VS EstimatesMTCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. MTCR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MTCR. In the last year negative earnings were reported.
  • Also next year MTCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTCR Price Earnings VS Forward Price EarningsMTCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTCR Per share dataMTCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MTCR's earnings are expected to grow with 23.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.17%
EPS Next 3Y23.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MTCR Dividend Analysis

5.1 Amount

  • No dividends for MTCR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MTCR Fundamentals: All Metrics, Ratios and Statistics

METACRINE INC

NASDAQ:MTCR (2/8/2023, 8:00:01 PM)

After market: 0.4701 -0.02 (-5.01%)

0.4949

0 (-0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-28
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners20.97%
Ins Owner Change0%
Market Cap21.07M
Revenue(TTM)N/A
Net Income(TTM)-38.19M
Analysts45.71
Price Target0.51 (3.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.9%
Min EPS beat(2)-21.38%
Max EPS beat(2)41.18%
EPS beat(4)3
Avg EPS beat(4)23.22%
Min EPS beat(4)-21.38%
Max EPS beat(4)50.05%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-75%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0
BVpS0.87
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.15
Quick Ratio 12.15
Altman-Z -5.64
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)34.15%
Cap/Depr(5y)122.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.16%
EPS Next Y70.87%
EPS Next 2Y36.17%
EPS Next 3Y23.37%
EPS Next 5Y12.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-29.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.24%
OCF growth 3YN/A
OCF growth 5YN/A

METACRINE INC / MTCR Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for METACRINE INC?

ChartMill assigns a fundamental rating of 3 / 10 to MTCR.


What is the valuation status of METACRINE INC (MTCR) stock?

ChartMill assigns a valuation rating of 3 / 10 to METACRINE INC (MTCR). This can be considered as Overvalued.


What is the profitability of MTCR stock?

METACRINE INC (MTCR) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for MTCR stock?

The Earnings per Share (EPS) of METACRINE INC (MTCR) is expected to grow by 70.87% in the next year.